Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
314 GBX | +1.95% | +4.67% | +10.95% |
Apr. 26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
Apr. 26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.95% | 3.3B | |
+33.43% | 700B | |
+27.32% | 569B | |
-5.12% | 358B | |
+19.59% | 330B | |
+4.89% | 287B | |
+16.11% | 236B | |
+6.54% | 202B | |
-9.00% | 197B | |
+4.26% | 161B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- HUTCHMED China : Combination Therapies Show Potential Antitumor Activities in Separate Phase 2 Trials in China